Compare Organon & Co. Common Stock (OGN) vs Patterson-UTI Energy Inc. Common Stock (PTEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Patterson-UTI Energy Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Patterson-UTI Energy Inc. Common Stock trades at $11.6 (market cap $4.39B). The key difference: Patterson-UTI Energy Inc. Common Stock is the larger of the two by market cap, and Patterson-UTI Energy Inc. Common Stock pays the higher dividend (3.48%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Patterson-UTI Energy Inc. Common Stock for 3 Days on average.
| OGN | PTEN | |
|---|---|---|
Market Cap | $3.62B | $4.39B |
Volume | 2,892,999 | 4,811,496 |
Sector | Health | Energy |
52-Week High | $13.81 | $13.15 |
52-Week Low | $5.70 | $5.41 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $11.04B | $5.47B |
Dividend Yield | 0.58% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Patterson-UTI Energy (PTEN) trades at $11.52, up 1.68% today, with a neutral technical signal. The stock shows strong cash flow from operations at $961.22M for 2025, but net income remains negative at -$93.64M. Recent earnings beats and an upcoming Q3 2026 report on October 29, 2026, highlight operational momentum, supported by an average of 103 drilling rigs in September 2026. Analyst consensus is bullish with a $13.38 price target, indicating a 16% upside.
The outlook is cautiously optimistic due to earnings consistency and positive analyst sentiment, but risks include persistent net losses, exposure to oil price volatility, and competitive pressures. Upside potential hinges on sustained rig demand and profitability improvements, while downside risks stem from macroeconomic headwinds affecting energy sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Patterson-UTI Energy Inc. Common Stock
Patterson-UTI Energy provides drilling, completion, and other oilfield services for oil and gas producers in the United States.
Read more on PTEN →
